Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIN Plus Sintilimab for Advanced pMMR/MSS Colorectal Cancer With Hepatic Metastases
NCT07411781Phase 1Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in colorectal cancer (CRC), sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence of treatment-related Adverse Events at 12 months and Immune response assessed by CD8+T cells with special phenotype up to 2 years. Planned start Mar 2026; status: not yet recruiting.
02
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07411781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07411781.